Rotenone and MPP+ preferentially redistribute apoptosis-inducing factor in apoptotic dopamine neurons

Maria L R Lim1, Linda D Mercer, Phillip Nagley

  • 1Department of Biochemistry and Molecular Biology, Monash University, Australia.

Neuroreport
|April 17, 2007
PubMed

Insights

Rotenone and 1-methyl-4-phenylpyridinium induce parkinsonism by affecting dopamine neurons. Apoptosis-inducing factor release precedes cytochrome c release, indicating caspase-independent signaling in these models.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Toxicology

Background:

  • Parkinson's disease models are crucial for understanding neurodegeneration.
  • Mitochondrial dysfunction is implicated in dopaminergic neuron loss in Parkinson's disease.
  • Apoptogenic proteins, such as apoptosis-inducing factor and cytochrome c, play key roles in programmed cell death.

Purpose of the Study:

  • To investigate the differential mitochondrial redistribution of apoptosis-inducing factor and cytochrome c in response to rotenone and 1-methyl-4-phenylpyridinium.
  • To determine the role of caspase-independent signaling in parkinsonian models induced by these toxins.

Main Methods:

  • Primary cultures of rat mesencephalic dopamine neurons were utilized.
  • Neurons were exposed to rotenone (30 nM) and 1-methyl-4-phenylpyridinium (300 μM) for 24 and 48 hours.
  • Apoptosis, and the mitochondrial redistribution of cytochrome c and apoptosis-inducing factor were quantified.

Main Results:

  • Rotenone exposure led to apoptosis in tyrosine hydroxylase-positive dopamine neurons.
  • Apoptosis-inducing factor release reached 40% at 24 hours with rotenone, while cytochrome c release reached this level at 48 hours.
  • 1-methyl-4-phenylpyridinium induced similar redistribution patterns for both proteins.
  • Preferential release of apoptosis-inducing factor before cytochrome c was observed.

Conclusions:

  • The findings suggest a predominant caspase-independent mitochondrial proapoptotic signaling pathway in rotenone- and 1-methyl-4-phenylpyridinium-induced parkinsonian models.
  • This differential release pattern highlights distinct aspects of mitochondrial-mediated apoptosis in dopaminergic neurodegeneration.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...